Nasogastric Tube After Laparoscopic Heller-Dor Myotomy

Sponsor
Federico II University (Other)
Overall Status
Completed
CT.gov ID
NCT05729971
Collaborator
(none)
79
1
46.9
1.7

Study Details

Study Description

Brief Summary

The goal of this prospective observational study is to evaluate the role of nasogastric tube (NGT) in patients with achalasia underwent to Heller-Dor laparoscopic. The main question it aims to answer are:

• If it is possible to remove NGT at the end of surgery. Participants will be dived in two groups: the first one with NGT after surgery and second one without NGT (noNGT).

If there is a comparison group: Researchers will compare group NGT and group noNGT to see if routine placement of NGT is useless.

Condition or Disease Intervention/Treatment Phase
  • Procedure: nasogastric tube

Detailed Description

Achalasia is a rare disease characterized by dysfunction of low oesophageal sphincter. This disease is divided according to Chicago classification into three subtypes.

Laparoscopic Heller - Dor is a important treatment of types I and II Achalasia. There are several studies evaluating the NGT in colorectal, hepatic, urologic, thoracic, otorhinolaryngology, gastric and esophageal surgery. Its use in postoperative period in achalasic patients is not yet clear.

Historically, NGT has been used to reduce gastric distention, nausea, vomiting and chest pain.

The aim of our study is to value the role of NGT for this surgery. We prospectively enrolled achalasic patients undergoing laparoscopic Heller -Dor .

The NGT group and noNGT were compared in terms of perioperative outcomes.

Study Design

Study Type:
Observational
Actual Enrollment :
79 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Nasogastric Tube After Laparoscopic Heller-Dor Myotomy: do You Really Need it?
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Jul 30, 2022
Actual Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
with NGT

In these patients, the nasogastric tube remains after surgery. It was removed after x-ray test.

Procedure: nasogastric tube
The intervention consists in removing or not the nasogastric tube at the end of the surgery.

noNGT

In these patients, NGT was removed at the end of surgery.

Outcome Measures

Primary Outcome Measures

  1. Nausea [in the first postoperative day]

    clinically evaluating the presence or absence

  2. vomiting [in the first postoperative day]

    clinically evaluating the presence or absence

  3. chest pain [in the first postoperative day]

    clinically evaluating the presence or absence

Secondary Outcome Measures

  1. Length of stay [from the first postoperative day to the third postoperative day]

    days of hospitalization from first postoperative day

  2. First flatus [from the first postoperative day to the third postoperative day]

    on which postoperative day the patient had the first flatus.

  3. Intake liquid diet [from the first postoperative day to the third postoperative day]

    when the patient starts drinking

  4. Intake semi-solid diet (day) [from the first postoperative day to the third postoperative day]

    when the patient starts to eat

  5. postoperative complications [from the first postoperative day to the third postoperative day]

    Based on Clavien-Dindo classification

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with achalasia of type I and II

  • patients undergoing laparoscopic Heller-Dor

  • patients older than 18 years

  • both sexes

Exclusion Criteria:
  • pregnant patients;

  • patients a history of abdominal surgery;

  • body mass index (BMI) >40;

  • American Society of Anesthesiology (ASA) score >4;

  • megaesophagus;

  • III type Achalasia;

  • previously treated for this disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 AOU. policlinico, Federico II Napoli Italy 800131

Sponsors and Collaborators

  • Federico II University

Investigators

  • Study Director: Giovanni Aprea, professor, Federico II University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Giuseppe Palomba, M.D, PhD student, Federico II University
ClinicalTrials.gov Identifier:
NCT05729971
Other Study ID Numbers:
  • 292/190
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 15, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by Giuseppe Palomba, M.D, PhD student, Federico II University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2023